leukemia treatment

Novel leukemia vaccine for high-risk patients

harminka — Tue, 04 Nov 2008 08:07:09 -0600

Researchers at the Moores Cancer Center at the University of California, San Diego (UCSD) are conducting clinical trials of a novel therapy aimed at revving up the immune system to combat a particularly difficult-to-treat form of leukemia.

New way to make a good anti-leukemia drug better

harminka — Mon, 20 Oct 2008 11:18:06 -0500

A recently identified cancer-causing protein makes the anti-leukemia drug imatinib, less effective. By blocking the protein, an international team of researchers was able to slow the spread of leukemia cells in culture.

Methadone breaks resistance in untreatable forms of leukemia

harminka — Fri, 01 Aug 2008 08:04:45 -0500

Researchers in Germany have discovered that methadone, an agent used to break addiction to opioid drugs, has surprising killing power against leukemia cells, including treatment resistant forms of the cancer.

Sparing leukemia Patients from unnecessary treatment

harminka — Wed, 30 Jul 2008 01:26:22 -0500

Nearly a third of leukemia patients do not respond to chemotherapy, but this is not usually discovered until they have already endured a week-long chemotherapy treatment and waited a month to see whether it has worked. A new study shows that PET scans could tell how well a patient is responding after just one day of chemotherapy.

Tumor-inhibiting protein could be effective in treating leukemia

harminka — Tue, 15 Jul 2008 08:33:34 -0500

Angiocidin, a tumor-inhibiting novel protein discovered by Temple University researchers, may also have a role as a new therapeutic application in treating leukemia, according to a study by the researchers.

Two suppressor molecules affect 70 genes in leukemia

harminka — Fri, 25 Apr 2008 06:27:12 -0500

By restoring two small molecules that are often lost in chronic leukemia, researchers were able to block tumor growth in an animal model.

Stem cell research leads to potential new therapy for rare blood disorder

harminka — Mon, 07 Apr 2008 11:40:48 -0500

A unique partnership between industry and academia has led to human clinical trials of a new drug for a rare class of blood diseases called myeloproliferative disorders (MPD), which are all driven by the same genetic mutation and can evolve into leukemia.

Molecular science could further improve leukemia survival, say St. Jude researchers

harminka — Fri, 21 Mar 2008 14:41:05 -0500

The dramatic increase that has occurred in the cure rate for children with acute lymphoblastic leukemia (ALL) will be difficult to replicate in older patients without considerable additional research, according to an article by St. Jude Children’s Research Hospital authors that appears in the March 22 issue of the Lancet.

Novel mechanism may boost impaired function of leukemia protein

harminka — Sat, 01 Mar 2008 01:48:20 -0600

A new study led by researchers at Memorial Sloan-Kettering Cancer Center (MSKCC) reports on a novel mechanism that can enhance the function of a protein that is frequently impaired in patients with acute forms of leukemia.

Molecules might identify high-risk acute-leukemia patients

harminka — Wed, 16 Jan 2008 07:49:45 -0600

New research suggests that certain small molecules used by cells to control the proteins they make might also help doctors identify adult acute-leukemia patients who are likely to respond poorly to therapy.

Scoring system identifies MDS patients who have low-risk disease

harminka — Sat, 22 Dec 2007 06:17:54 -0600

A new scoring system for a form of leukemia known as myelodysplastic syndrome (MDS) identifies patients who appear to have low-risk disease but actually have poor prospects of survival, researchers at The University of Texas M. D. Anderson Cancer Center report online at the journal Leukemia.

Test for targeted therapy in acute myeloid leukemia

harminka — Mon, 10 Dec 2007 14:03:57 -0600

Oregon Health & Science University Cancer Institute researcher Jeff Tyner, Ph.D., has created a way to identify proteins that are candidates for targeted therapy in acute myeloid leukemia using an assay that yields results in just four days.